Trial · NCT04169373
Participant flow140
How many started, completed or left each group, period by period.
1 to 20 of 140
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Double Blind (DB): Week 1 - 14 or 52 | STARTED | DB Study 1: Placebo | 209 | |
| Double Blind (DB): Week 1 - 14 or 52 | STARTED | DB Study 1: Upadacitinib 15 mg | 211 | |
| Double Blind (DB): Week 1 - 14 or 52 | STARTED | DB Study 2: Placebo | 158 | |
| Double Blind (DB): Week 1 - 14 or 52 | STARTED | DB Study 2: Upadacitinib 15 mg | 156 | |
| Double Blind (DB): Week 1 - 14 or 52 | STARTED | OL Study 1: Upadacitinib 15 mg | 0 | |
| Double Blind (DB): Week 1 - 14 or 52 | STARTED | OL Study 2: Upadacitinib 15 mg | 0 | |
| Double Blind (DB): Week 1 - 14 or 52 | STARTED | RW Study 1: Off Upadacitinib - No Flare | 0 | |
| Double Blind (DB): Week 1 - 14 or 52 | STARTED | RW Study 2: Off Upadacitinib - No Flare | 0 | |
| Double Blind (DB): Week 1 - 14 or 52 | STARTED | RW Study 1: Upadacitinib 15 mg - No Flare | 0 | |
| Double Blind (DB): Week 1 - 14 or 52 | STARTED | RW Study 2: Upadacitinib 15 mg - No Flare | 0 | |
| Double Blind (DB): Week 1 - 14 or 52 | STARTED | RW Study 1: Upadacitinib 15 mg - Flare | 0 | |
| Double Blind (DB): Week 1 - 14 or 52 | STARTED | RW Study 2: Upadacitinib 15 mg - Flare | 0 | |
| Double Blind (DB): Week 1 - 14 or 52 | STARTED | RW Study 1: Upadacitinib 15 mg - Extension | 0 | |
| Double Blind (DB): Week 1 - 14 or 52 | STARTED | RW Study 2: Upadacitinib 15 mg - Extension | 0 | |
| Double Blind (DB): Week 1 - 14 or 52 | Received Study Drug | DB Study 1: Placebo | 209 | |
| Double Blind (DB): Week 1 - 14 or 52 | Received Study Drug | DB Study 1: Upadacitinib 15 mg | 211 | |
| Double Blind (DB): Week 1 - 14 or 52 | Received Study Drug | DB Study 2: Placebo | 157 | |
| Double Blind (DB): Week 1 - 14 or 52 | Received Study Drug | DB Study 2: Upadacitinib 15 mg | 156 | |
| Double Blind (DB): Week 1 - 14 or 52 | Received Study Drug | OL Study 1: Upadacitinib 15 mg | 0 | |
| Double Blind (DB): Week 1 - 14 or 52 | Received Study Drug | OL Study 2: Upadacitinib 15 mg | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04169373/flow